| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.001 | 1 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.001 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00076 | 1 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.00077 | 1 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.00068 | 1 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.00055 | 1 |